Pierre Cybulski

Mr. Pierre Cybulski

Molecular imaging and photonics, chemistry department, KU Leuven, Belgium
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Indra Van ZundertIndra Van Zundert
Indra Van Zundert
Maria mariabravoMaria mariabravo
Maria mariabravo
Olivier DeschaumeOlivier Deschaume
Olivier Deschaume
Pierre CybulskiPierre Cybulski
Pierre Cybulski
Carmen BarticCarmen Bartic
Carmen Bartic
Susana RochaSusana Rocha
Susana Rocha
The application of antibodies in nanomedicine is now standard practice in research since it represents an innovative approach to deliver chemotherapy agents selectively to tumors. The variety of targets or markers that are overexpressed in different types of cancers results in a high demand for antibody conjugated-nanoparticles, which are versatile and easily customizable. Considering up-scaling, the synthesis of antibody-conjugated nanoparticles should be simple and highly reproducible. Here, we developed a facile coating strategy to produce antibody-conjugated nanoparticles using ‘click chemistry’ and further evaluated their selectivity towards cancer cells expressing different markers. Our approach was consistently repeated for the conjugation of antibodies against CD44 and EGFR, which are prominent cancer cell markers. The functionalized particles presented excellent cell specificity towards CD44 and EGFR overexpressing cells, respectively. Our results indicated that the developed coating method is reproducible, versatile, and non-toxic, and can be used for particle functionalization with different antibodies. This grafting strategy can be applied to a wide range of nanoparticles and will contribute to the development of future targeted drug delivery systems.